Veran Medical Launches New Lung Navigation Software to Enable Faster Diagnosis and Earlier Treatment of Lung Cancer
St. Louis, MO (PRWEB) May 16, 2017 -- Veran Medical continues to rapidly innovate with the launch of new lung navigation software for their SPiN Thoracic Navigation System™. The next generation SPiN Drive® navigation software will debut at the American Thoracic Society annual meeting in Washington, D.C. on May 21-23 (booth #657). Veran’s SPiN System™, new lung navigation software, and navigated instrumentation are designed to continue to drive consistently higher bronchoscopy diagnostic yields and the faster diagnosis of lung cancer. The earlier patients are diagnosed, the faster they can receive life saving therapy and improve chances of survival.
Veran’s new SPiN Drive® navigation software continues to improve their already best-in-class software for Navigated Bronchoscopy and Navigated TTNA (SPiN Perc™) to sample suspicious lung lesions. The SPiN System™ is now capable of displaying a Volume Rendered (VR) View, enabling physicians to visualize and avoid blood vessels during a Navigated Bronchoscopy. The next generation SPiN Drive® software will now enable physicians to utilize the SPiN System™ for additional therapy delivery solutions – with new features including percutaneous ablation modeling, and percutaneous fiducial marker visualization and reporting using SPiN Perc™. These new software capabilities continue to expand the clinical value and utilization scenarios for the SPiN System™.
“We are excited to debut our next generation SPiN Drive® software to all the lung specialists attending ATS,” said Veran Medical CEO, Jason Pesterfield. “This new lung navigation software assists these physicians in the early detection and treatment of lung cancer and in turn helps us continue our mission to significantly improve long-term survival rates for lung cancer patients.”
Veran’s next generation SPiN Thoracic Navigation System™ offers an industry leading precision thoracic guidance platform that allows lung experts to seamlessly transition between a navigated endobronchial approach and a navigated transthoracic approach utilizing SPiN Perc™, to help physicians rapidly and definitively diagnose lung cancer. Published clinical studies utilizing a multi-modality approach, including Veran’s SPiN System™ and SPiN Perc™, have demonstrated a 92% diagnostic yield.
Lung Cancer remains the number one cancer killer in the United States. 94 million current or former smokers remain at elevated risk. More than 8 million people in the U.S. currently meet the criteria for lung cancer screening. When suspicious lesions are discovered, patients need answers. But mounting clinical data suggests that a large percentage of the hundreds of thousands of bronchoscopies performed every year on suspected lung cancer patients are non-diagnostic—delaying potential life saving therapy.
About Veran Medical Technologies
Veran is a privately held medical device company headquartered in St. Louis, MO. The company’s main focus is assisting physicians in the early diagnosis and treatment of lung cancer. In the United States, lung cancer kills more people each year than breast, prostate, pancreatic and colon cancers combined.
Veran has developed and commercialized an FDA cleared, next generation electromagnetic thoracic navigation platform called the SPiN Thoracic Navigation System™. Veran’s breakthrough technology has been adopted by leading cancer centers throughout the United States. Veran provides physicians with a full line of bronchoscopic brushes, needles, forceps and steerable catheters with tiny electromagnetic sensors embedded in the tips for precise navigation. The combination of these proprietary Always-On Tip Tracked® instruments and Veran’s exclusive patient respiratory gating technology enables physicians to accurately access lung nodules by accounting for nodule movement during patient breathing, a common challenge for lung specialists.
Another challenge lung specialists face is that approximately 40% of lung nodules lie outside of an airway, making them very difficult to reach endobronchially, and traditionally requiring an additional procedure. Veran’s SPiN Thoracic Navigation System™ is the first and only FDA cleared technology that enables Pulmonologists or Thoracic Surgeons to safely and accurately access lung nodules outside of an airway using SPiN Perc™, a navigated transthoracic needle. With SPiN Perc™, Veran combines endobronchial navigation with percutaneous navigation, allowing physicians to access all lung nodules in a single procedure, regardless of nodule size or location. This eliminates the cost and risk of unnecessary procedures and empowers physicians to provide a same day diagnosis for their patients. The early diagnosis and treatment of lung cancer has been proven to save lives.
TJ Meyer, Veran Medical Technologies, http://www.veranmedical.com, +1 314-659-8500, [email protected]
Share this article